A newly designed backpack, incorporating aerospace technology, shows promise as a balance aid for patients with the movement disorder ataxia. Research conducted by Radboud university medical center, ...

Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

The FDA rejected PTC Therapeutics' NDA for vatiquinone, citing insufficient efficacy evidence and requiring an additional study for resubmission. The MOVE-FA trial, a Phase II/III study, failed to ...

The FDA requires more evidence of efficacy for vatiquinone, a 15-lipoxygenase inhibitor, before approval for Friedreich ataxia treatment. Vatiquinone showed improvement in bulbar and upright stability ...

The U.S. Food and Drug Administration has turned away PTC Therapeutics' proposed vatiquinone treatment for the rare, inherited neurodegenerative disorder Friedreich's ataxia over concerns about the ...

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. PTC Therapeutics, Inc. is one of them. PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biotechnology company ...

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA). In May ...

It looks like Biogen Inc.’s Nrf2 activator, Skyclarys (omaveloxolone), will maintain its status as the sole therapy approved for treating patients with Friedreich’s ataxia (FA), at least for now. The ...

Colon cancer, primarily affecting the large intestine and rectum, can manifest rare skin symptoms like nodules, rashes, or pigmentation changes, indicating potential spread. A study from NCBI ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. Xoma is set to acquire Mural for $2.035 per share, for a total value of about ...